John C. Mc Kew is Chief Scientific Officer of LUMOS PHARMA, INC.. Currently has a direct ownership of 12,653 shares of LUMO, which is worth approximately $55,293. The most recent transaction as insider was on Aug 06, 2024, when has been sold 3,407 shares (Common Stock) at a price of $1.89 per share, resulting in proceeds of $6,439. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 12.7K
21.21% 3M change
32.36% 12M change
Total Value Held $55,293

John C. McKew Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 06 2024
SELL
Open market or private sale
$6,439 $1.89 p/Share
3,407 Reduced 21.21%
12,653 Common Stock
Aug 01 2024
SELL
Payment of exercise price or tax liability
$2,851 $1.79 p/Share
1,593 Reduced 9.02%
16,060 Common Stock
Apr 03 2024
SELL
Open market or private sale
$6,132 $2.77 p/Share
2,214 Reduced 11.43%
17,153 Common Stock
Apr 01 2024
SELL
Payment of exercise price or tax liability
$2,942 $2.84 p/Share
1,036 Reduced 5.08%
19,367 Common Stock
Apr 01 2024
BUY
Grant, award, or other acquisition
$5,680 $2.84 p/Share
2,000 Added 8.93%
20,403 Common Stock
Feb 06 2024
SELL
Open market or private sale
$1,327 $3.03 p/Share
438 Reduced 2.32%
18,403 Common Stock
Feb 01 2024
SELL
Payment of exercise price or tax liability
$1,101 $3.01 p/Share
366 Reduced 1.91%
18,841 Common Stock
Aug 02 2023
SELL
Open market or private sale
$10,936 $3.21 p/Share
3,407 Reduced 15.41%
18,707 Common Stock
Aug 01 2023
SELL
Payment of exercise price or tax liability
$5,225 $3.28 p/Share
1,593 Reduced 6.72%
22,114 Common Stock
Apr 04 2023
SELL
Open market or private sale
$7,239 $3.27 p/Share
2,214 Reduced 8.71%
23,207 Common Stock
Apr 01 2023
SELL
Payment of exercise price or tax liability
$3,429 $3.31 p/Share
1,036 Reduced 3.92%
25,421 Common Stock
Feb 02 2023
SELL
Open market or private sale
$1,549 $3.53 p/Share
439 Reduced 1.63%
26,457 Common Stock
Feb 01 2023
SELL
Payment of exercise price or tax liability
$725 $3.52 p/Share
206 Reduced 0.76%
26,896 Common Stock
Feb 01 2023
BUY
Grant, award, or other acquisition
$7,040 $3.52 p/Share
2,000 Added 6.87%
27,102 Common Stock
Aug 02 2022
SELL
Open market or private sale
$27,631 $8.11 p/Share
3,407 Reduced 12.16%
24,602 Common Stock
Aug 01 2022
SELL
Payment of exercise price or tax liability
$13,015 $8.17 p/Share
1,593 Reduced 5.38%
28,009 Common Stock
Jun 06 2022
SELL
Open market or private sale
$1,288 $7.62 p/Share
169 Reduced 0.58%
29,102 Common Stock
Apr 05 2022
SELL
Open market or private sale
$18,420 $8.32 p/Share
2,214 Reduced 7.03%
29,271 Common Stock
Apr 01 2022
SELL
Payment of exercise price or tax liability
$9,562 $9.23 p/Share
1,036 Reduced 3.19%
31,485 Common Stock
Feb 01 2022
SELL
Payment of exercise price or tax liability
$1,002 $10.02 p/Share
100 Reduced 0.31%
32,521 Common Stock
Feb 01 2022
BUY
Grant, award, or other acquisition
$15,030 $10.02 p/Share
1,500 Added 4.4%
32,621 Common Stock
Sep 08 2021
SELL
Open market or private sale
$25,018 $11.3 p/Share
2,214 Reduced 6.66%
31,012 Common Stock
Aug 01 2021
BUY
Grant, award, or other acquisition
-
20,000 Added 37.58%
33,226 Common Stock
Apr 01 2021
SELL
Payment of exercise price or tax liability
$12,691 $12.25 p/Share
1,036 Reduced 7.26%
13,226 Common Stock
Feb 01 2021
BUY
Grant, award, or other acquisition
-
1,078 Added 7.03%
14,262 Common Stock
JCM

John C. Mc Kew

Chief Scientific Officer
Austin, TX

Track Institutional and Insider Activities on LUMO

Follow LUMOS PHARMA, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LUMO shares.

Notify only if

Insider Trading

Get notified when an Lumos Pharma, Inc. insider buys or sells LUMO shares.

Notify only if

News

Receive news related to LUMOS PHARMA, INC.

Track Activities on LUMO